Reversible detyrosination of a-tubulin is crucial to microtubule dynamics and functions, and defects have been implicated in cancer, brain disorganization, and cardiomyopathies. The identity of the tubulin tyrosine carboxypeptidase (TCP) responsible for detyrosination has remained unclear. We used chemical proteomics with a potent irreversible inhibitor to show that the major brain TCP is a complex of vasohibin-1 (VASH1) with the small vasohibin binding protein (SVBP). VASH1 and its homolog VASH2, when complexed with SVBP, exhibited robust and specific Tyr/Phe carboxypeptidase activity on microtubules. Knockdown of vasohibins or SVBP and/or inhibitor addition in cultured neurons reduced detyrosinated a-tubulin levels and caused severe differentiation defects. Furthermore, knockdown of vasohibins disrupted neuronal migration in developing mouse neocortex. Thus, vasohibin/SVBP complexes represent long-sought TCP enzymes.
M
icrotubules are cytoskeletal polymers of a/b tubulin dimers centrally involved in cell division, motility, and morphogenesis. In the detyrosination/tyrosination cycle of tubulin, the C-terminal tyrosine of a-tubulin is removed by an elusive peptidase [tyrosine carboxypeptidase (TCP)] and re-added by the tubulin tyrosine ligase (TTL) (1) . This cycle, which is specific to a-tubulin and mostly conserved from chordates to mammals, has a vital role in vivo (2) . Tubulin detyrosination and tyrosination of a-tubulin is an important regulatory signal for mitosis (3) (4) (5) , neuronal physiology (6) (7) (8) , and muscle mechanotransduction (9, 10) . Consequently, abnormal tyrosination levels are associated with cell transformation and tumor aggressiveness (11, 12) , neuronal disorganization (2) , and heart failure and cardiomyopathies (10, 13) . Although the detyrosination reaction was first described 40 years ago (14) , the identity of TCP has remained unknown.
To enrich for TCP, we designed a three-step purification procedure using taxol-stabilized radiolabeled tyrosinated microtubules as a substrate to follow activity. A typical procedure gave a final purification factor of nearly 400-fold ( Fig. 1A  and fig. S1A ). The last fraction (IV) was able to cleave the C-terminal tyrosine from tubulin incorporated in microtubules but not from EB1 ( fig. S1B ). EB1 is a protein that shares a similar C-terminal sequence with a-tubulin (-QEEY instead of -GEEY) and is generally not a substrate for TCP in physiological contexts (15) .
To isolate the protein(s) responsible for TCP activity from fraction IV, we reasoned that an irreversible inhibitor could be used as in other chemical proteomic studies (16) . We tested the sensitivity of brain TCP to various commercial protease inhibitors. The activity was inhibited by several serine/cysteine protease inhibitors [4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), Tosyl-L-lysyl-chloromethyl ketone (TLCK), Tosyl phenylalanyl chloromethyl ketone (TPCK), E-64, and parthenolide] and by the thiolreactive compound N-ethylmaleimide (Fig. 1B and  fig. S2A ). These results, in agreement with prior studies (17) , strongly suggested that the catalytic activity of the putative TCP depends on a catalytic cysteine.
Although E-64 only showed modest inhibitory activity [median inhibitory concentration (IC 50 ) around 300 mM] (Fig. 1B) , it is an ideal starting point for inhibitor design because its reactive epoxide electrophile can display a peptide-or amino acid-mimicking native protein C terminus. Furthermore, parthenolide, which is widely used to down-regulate detyrosination levels in cells (4, 6, 9, 10) , contains an epoxide function that is essential to its cellular effect (17) . We thus synthesized three inhibitors-epoY, epoEY, and epoEEY-which contain the epoxide coupled to one, two, or three amino acids from the a-tubulin C terminus, respectively ( fig. S2B ). EpoY was the most potent inhibitor of the TCP activity (IC 50 around 500 nM) (Fig. 1B) . Alkyne-epoY, which retained a strong inhibitory potency (Fig. 1 , B and C) and irreversibly inhibited the activity ( fig. S2, C and D) , was used to perform tetramethylrhodamine (TAMRA) labeling of fraction IV by means of click chemistry (Fig. 1D) . This labeling showed specific modification of a small number of proteins (Fig. 1E) . We then purified the inhibitor targets using agarose beads and, after on-beads trypsin digestion and quantitative mass spectrometry analyses of the resulting peptides from three independent experiments, we identified the protein vasohibin-1 (VASH1) as the most likely TCP candidate ( Fig. 1D and tables S1 and S2). Peptides covering the almost full VASH1 sequence were detected ( fig. S2E ). Furthermore, recent bioinformatics data show that Vasohibin-1 and its homolog vasohibin-2 (VASH2) possess a noncanonical Cys-His-Ser catalytic triad and are members of the transglutaminase-like cysteine proteases family ( Fig. 1F) (18) .
Vasohibin proteins (41 to 42 kDa) have been extensively characterized as angiogenesis regulators but are poorly understood on a molecular level (19) . Small vasohibin binding protein (SVBP) (Ccdc23) is a high-affinity binding partner of vasohibins that has a chaperone-like function (20) . We examined the ability of VASH proteins to detyrosinate a-tubulin in cells in the absence or presence of SVBP. Expression of vasohibins alone in human embryonic kidney (HEK) 293T cells resulted in a slight increase of detyrosinated tubulin, whereas expression of either protein with SVBP resulted in a substantial increase in detyrosinated tubulin corresponding to a nearly complete loss of endogenous tyrosinated tubulin ( Fig. 2A) . Mutation of the putative catalytic cysteine on vasohibins [C179A for VASH1 and C158A for VASH2 (18) ] abolished their capacity to produce detyrosinated tubulin. (Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr. In the mutants, amino acids were substituted at certain locations; for example, C179A indicates that cysteine at position 179 was replaced by alanine.) Similarly, in mouse embryonic fibroblasts (MEFs), expression of the vasohibins with SVBP resulted in complete detyrosination of endogenous a-tubulin (Fig. 2B  and fig. S3A ).
a-Tubulins are generally encoded with a Cterminal tyrosine preceded by two glutamates. a4-Tubulin lacks the C-terminal tyrosine, and a8-tubulin contains a C-terminal phenylalanine residue. Phenylalanine can be incorporated in place of tyrosine in tubulin and be a possible cause of neuronal dysfunction (21) . We tested the substrate specificity of the vasohibins by overexpressing a1B-and a8-tubulin together with VASH1 or VASH2 and SVBP in HEK293T cells. Both tubulin isotypes were cleaved by active vasohibins when expressed with SVBP ( Fig. 2C  and fig. S3B ). Vasohibins were unable to cleave the C-terminal residue when tyrosine was mutated to alanine ( Fig. 2C and fig. S3B ), confirming the specificity of VASH proteins for C-terminal tyrosine and phenylalanine residues.
We overexpressed vasohibins in HEK293T cells in the absence or presence of SVBP and purified the resulting complexes using a cobalt resin. SVBP copurified with both vasohibins as expected from previous affinity measurements [dissociation constant (K d ) 30 to 90 nM] (20) , and complex formation was not dependent on catalytic activity ( fig. S4A ). The two protein complexes efficiently catalyzed tubulin detyrosination, whereas complexes containing the catalytic dead versions of the vasohibins were unable to detyrosinate tubulin (Fig. 2D ). Both complexes cleaved microtubules more rapidly as compared with tubulin dimers (Fig. 2E and fig. S4B ), which is consistent with the reported preference of brain TCP in in vitro experiments (1, 22, 23) . Purified VASH1/SVBP complex was not able to cleave the C-terminal tyrosine from EB1, indicating its clear tubulin preference. Intriguingly, VASH2/SVBP complex was able to partially detyrosinate EB1 in the same conditions (Fig. 2F ). In most cell types, including neuronal-derived cells, C-terminal tyrosine cleavage is restricted to tubulin (1, 15) . EB1 can, however, be detyrosinated in specific endothelial and tumor cells (24) , and this may be related to their VASH2 contents or defect in a regulatory mechanism.
To confirm the functional importance of vasohibins and their role in a-tubulin detyrosination, we assessed the phenotypic effects of knocking down expression of these proteins in differentiating neurons, where the detyrosination/ tyrosination cycle is highly important for growth cone pathfinding and axon differentiation-that is, for neuron polarization (2, 7, 8) . Although we were unable to detect vasohibins and SVBP by means of immunoblot in mouse neurons using commercial antibodies, we amplified their transcripts from RNA preparations of cultured hippocampal neurons as well as of adult and embryonic mouse brain tissues (Fig. 3A and figs. S5A and S6A). We transfected hippocampal neurons with plasmids expressing short hairpin RNAs (shRNAs) targeting either the vasohibins or SVBP (validated in figs. S5B and S6B) as well as control shRNAs. The levels of detyrosinated a-tubulin were decreased by almost 50% when the two vasohibins, or the SVPB, were down-regulated. Addition of inhibitor (alkyne-epoY) also largely reduced detyrosinated a-tubulin (Fig. 3, B and C) . When added together with the shRNAs, levels of detyrosinated tubulin were decreased up to 75% (Fig. 3 , B and C). The remaining pool of detyrosinated a-tubulin could be due to incomplete depletion of vasohibins activities or to the presence of a4-tubulin, which genetically lacks the C-terminal tyrosine and remains in detyrosinated form in the brain (25) . The occurrence of other detyrosinases can however not be excluded. Confocal images of neurons cultured 2 days in vitro (2DIV) confirmed a decrease in the levels of the native detyrosinated a-tubulin upon reduction of vasohibins expression or addition of inhibitor ( Fig.  3D and fig. S5C ). The remaining detyrosinated pools were specifically concentrated in the axon, whereas a-tubulin in the other neurites appeared highly tyrosinated. Vasohibins down-regulation led to a clear delay in axonal differentiation (Fig. 3E) . Tau and ankyrin G staining of neurons bearing an axon confirmed normal distribution, with Tau highly expressed in axon shaft at 3DIV and ankyrin G in the axon initial segment at 10DIV ( fig. S7 ). Neurons 2DIV knocked down for vasohibins developed an increased number of neurites and branches with overall reduced axon length (Fig. 3F) layer organization (2) . During corticogenesis, neuronal migration relies in part on neuron polarization, which was highly dependent on vasohibins (Fig. 3, D and E) and SVBP ( fig. S6 , D and E). We electroporated embryonic day 14.5 (E14.5) embryos with the plasmids expressing shRNAs that target the vasohibins as well as control shRNA, and analyzed radial neuronal migration 4 days later. At E18.5, most neurons from control brains had reached the upper layer (bin 1), whereas when vasohibins were downregulated, a significant fraction of neurons failed to do so (Fig. 4, A and B) . Thus, these enzymes have a crucial role in neuronal migration during brain cortex development. TCP remained the crucial missing element of the a-tubulin detyrosination/tyrosination cycle for 40 years. We identified vasohibins as enzymatic 4 (F) Morphometric analyses of at least 85 neurons (2DIV) by using AutoNeuriteJ macro (details are available in the supplementary materials, materials and methods) on immunofluorescence images generated as in (D) (mean ± SEM, Mann-Whitney tests). In (C), (E), and (F): *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
proteins that perform the TCP function ( fig. S8 ). The failure of prior attempts to identify TCPs most probably resulted from their association with SVBP for stability and activity, which could likely be lost during standard purification assays. In agreement with TCP functions, vasohibins are widely distributed in eukaryotes and have broad tissue expression, and vasohibin-1 (which is generally more expressed than vasohibin-2) is abundant in the brain, heart, and kidney [ (18, 26, 27) and GTEx Portal, on www.gtexportal.org/home]. Additionally, we demonstrated their critical role in neuron and brain physiology. -neurons per embryo), mean ± SEM. n.s., not significant; ***P < 0.001, ****<0.0001 (Mann-Whitney test).
